Good MorningEquity markets shrugged off the risk of a widening Middle Eastern conflict in favor of the interest rate and earnings outlook. With interest rates falling and expected to continue falling in 2025, S&P 500 earnings will continue to grow and build value for investors. In this scenario, the market can continue to rise indefinitely, and new highs will likely occur as the quarters progress. The technical target is now 6,000 and may be reached by year's end.
This week's risk is the CPI report on Thursday. Analysts forecast headline inflation to cool compared to last month and last year, keeping the FOMC on pace to cut rates again this year. The risk is two-fold: cooler-than-expected data could raise fears of a recession, while hotter-than-expected data will keep the FOMC from cutting as aggressively as indicated. The takeaway for investors is that S&P 500 volatility will remain high for the foreseeable future. Featured: Elon’s big $266,000 per second purchase (Ad) 
|
Medical | |
The medical device market, a powerhouse sector, is projected to exceed $600 billion by 2025. This growth is fueled by a combination of factors, including an aging population, rising healthcare costs, and rapid technological advancements powered by advanced artificial intelligence (AI) and biotechn... Read the Full Story |
|
From Our Partners | | Bill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97.
It's a single-page, seven-point filter designed to help traders identify weak setups before placing any options trade. Print it, keep it at your desk, and run it before every trade. The download link expires soon. | | Download your free copy of the Smart Trade Options Checklist now |
|
Technology | |
Momentum trading involves buying rising stocks with the idea that they will continue rising. While reminiscent of the greater fools theory, momentum trading is more than buying high and selling high. Good momentum trades combine factors that help ensure the market is bullish and capable of continu... Read the Full Story |
|
Consumer Discretionary | |
Every once in a while, a few stocks come under attack from short-selling firms or, essentially, by anyone that doesn’t align with that stock’s business or interests. It is tricky for retail investors to figure out whether short reports and attacks have any traction since they can often... Read the Full Story |
|
From Our Partners | | Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security.
The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move. | | Watch the documentary briefing and find out which side you land on |
|
Markets | |
Though it hasn’t been without its ups and downs, Apple Inc’s (NASDAQ: AAPL) stock has effectively been trading sideways since July. In fact, the tech titan’s shares closed Tuesday’s session at the same price they were just one week before they popped to their last all-time ... Read the Full Story |
|
Aerospace | |
The aerospace and defense industry has been a sustained beacon of strength in an otherwise volatile market. With geopolitical tensions escalating, including the ongoing Russia-Ukraine war and conflicts in the Middle East, the sector has steadily risen with momentum. Two giants in the industry, Loc... Read the Full Story |
|
From Our Partners | | Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now.
Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen.
Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch. | | Watch how to access the legal backdoor before it closes. |
|
Consumer Staples | |
There is a significant shift in institutional activity for Helen of Troy (NASDAQ: HELE) shares. The institutions shifted from selling to buying in Q3, creating a solid tailwind due to the high interest. Institutions own nearly 99% of this stock, leaving less than 1.5% for insiders, retail investor... Read the Full Story |
|
Finance | |
It might be surprising for some to hear that 2024 has been a great year for stocks in the insurance industry. In fact, every single large-cap insurance stock in the United States and Canada trading region has a positive return this year. Additionally, the iShares U.S. Insurance ETF (NYSEARCA: IAK)... Read the Full Story |
|
Retail/Wholesale | |
The market’s price action and attention are making a new shift this quarter. For most of 2024, everyone wanted to find the next best thing in the United States technology sector, as the semiconductor industry saw massive rallies in shares of NVIDIA Co. (NASDAQ: NVDA). However, it seems that ... Read the Full Story |
|
Medical | |
Skye Bioscience (NASDAQ: SKYE) is a micro-cap pharmaceutical company that is striving to become the next big thing in the weight loss drug space. The massive success of glucagon-like peptide-1 (GLP-1) agonist drugs sold by Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) has prompted Wall Stre... Read the Full Story |
|
Markets | |
Driven by demand from cloud computing and AI, semiconductor sales have skyrocketed in recent months as pressure due to supply chain concerns and inflation has eased. The specialized chips that power these popular technologies are in such high demand that makers of these products now represent thre... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel. | | View Today's Stock Pick |
|
